#United States #Los Angeles #Securities Fraud #Capricor Therapeutics #SBS Law

Investors of Capricor Therapeutics Face Securities Fraud Suit

In a significant move for shareholders, Schall, Brown & Schwartz LLP (SBS), a leading national shareholder rights litigation firm, has issued a reminder regarding a class action lawsuit against Capricor Therapeutics, Inc. This action stems from alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5 set forth by the U.S. Securities and Exchange Commission (SEC).

The class action covers a specific period between December 17, 2025, and July 26, 2026, during which investors who acquired shares of Capricor are encouraged to reach out to the firm regarding potential lead plaintiff appointments, although participation as a lead plaintiff is not a prerequisite for recovery.

Significant Dates and Details

The lawsuit's deadline for participation is September 28, 2026. All shareholders who believe they have incurred losses during the class period are urged to make contact with the lawyers at SBS to provide details of their investments. The complaint outlines that Capricor made materially misleading statements to the market. In particular, it highlights that the company altered the statistical analysis plan meant for evaluating its clinical data tied to Deramiocel. Notably, these adjustments were made despite the lack of FDA approval concerning the changes before the resubmission of its Biologics License Application (BLA).

Moreover, the company found itself facing a daunting risk as the FDA potentially deemed the evidence provided insufficient for Deramiocel's effectiveness. As a result, the subsequent public statements released by Capricor were alleged to be both false and misleading throughout the class period. Once these revelations became public, investors suffered losses due to the decline in the company's stock price.

How to Participate

Investors who experienced financial repercussions from their engagement with Capricor Inc. are encouraged to participate in this lawsuit as a pathway to recover their damages. Interested shareholders can reach out to Brian Schall or David Schwartz at Schall, Brown & Schwartz LLP. Their office, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, is open for inquiries at 310-301-3335. Additionally, investors can also engage with the firm through its official website or email for a free discussion of their rights. This can provide clarity on their legal standing and potential recovery actions.

It’s crucial for potential participants to note that the class in this case is still pending certification. Hence, individuals who opt to remain passive will remain absent class members, potentially missing the chance for recovery.

Why Choose SBS?

Schall, Brown & Schwartz LLP has a rich history of advocating for investors across the globe. Their expertise specifically in securities class action lawsuits and shareholder rights litigation puts them in a unique position to support affected investors vigorously. The firm’s leadership, comprised of experienced partners such as Brian Schall, Andrew Brown, and David Schwartz, pledges to fight for every investor's rights diligently.

In conclusion, the ongoing developments surrounding Capricor Therapeutics present significant implications for its shareholders, and the SBS team stands ready to support those impacted. Protect your investments and consider participating in this class action suit for a chance to reclaim losses incurred during this tumultuous period in the market.